Skip to main content
Top
Published in: Diabetologia 10/2009

01-10-2009 | Article

Is islet autoimmunity related to insulin sensitivity or body weight in children of parents with type 1 diabetes?

Authors: C. Winkler, S. Marienfeld, M. Zwilling, E. Bonifacio, A.-G. Ziegler

Published in: Diabetologia | Issue 10/2009

Login to get access

Abstract

Aims/hypothesis

It has been suggested that metabolic demand and insulin resistance play a role in the development of type 1 diabetes, including the onset of autoimmunity. The aim of the present study was to determine whether insulin demand is increased in children with islet autoantibodies.

Methods

BMI standard deviation score (BMI-SDS) was measured from 2 years of age in 1,650 prospectively followed children of mothers or fathers with type 1 diabetes, including 135 who developed persistent islet autoantibodies. HOMA of insulin resistance (HOMA-IR) was determined using fasting samples from 777 of the children starting from age 5 years.

Results

An increased HOMA-IR was associated with female sex (p = 0.0004), older age (p < 0.0001) and increased BMI-SDS (p < 0.0001). Children with islet autoantibodies did not have an increased HOMA-IR compared with age-matched islet autoantibody-negative children (age 8 years: mean 0.61 vs mean 0.72, respectively, p = 0.21; age 11 years: mean 0.96 vs mean 1.21, respectively, p = 0.07). Furthermore, after correction for age and sex, autoantibody positivity was associated with decreased HOMA-IR values (p = 0.01). BMI-SDS was similar between islet autoantibody-positive and -negative children at age 2 (mean 0.07 vs mean 0.16, respectively), 5 (mean 0.06 vs 0.08, respectively), 8 (mean − 0.09 vs mean 0.02, respectively), and 11 years (mean 0.22 vs mean 0.16, respectively) and similar to that of national reference values.

Conclusions/interpretation

Islet autoantibody-positive children in the BABYDIAB cohort are not insulin resistant and do not have an increased BMI around and early after islet autoantibody seroconversion. These findings are inconsistent with the notion that insulin resistance is a risk factor for islet autoimmunity.
Literature
1.
go back to reference Achenbach P, Bonifacio E, Koczwara K, Ziegler AG (2005) Natural history of type 1 diabetes. Diabetes 54(Suppl 2):S25–31PubMedCrossRef Achenbach P, Bonifacio E, Koczwara K, Ziegler AG (2005) Natural history of type 1 diabetes. Diabetes 54(Suppl 2):S25–31PubMedCrossRef
2.
go back to reference Atkinson MA, Eisenbarth GS (2001) Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358:221–229PubMedCrossRef Atkinson MA, Eisenbarth GS (2001) Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358:221–229PubMedCrossRef
3.
4.
go back to reference Wilkin TJ (2001) The accelerator hypothesis: weight gain as the missing link between type 1 and type 2 diabetes. Diabetologia 44:914–922PubMedCrossRef Wilkin TJ (2001) The accelerator hypothesis: weight gain as the missing link between type 1 and type 2 diabetes. Diabetologia 44:914–922PubMedCrossRef
5.
go back to reference Dahlquist G (2006) Can we slow the rising incidence of childhood-onset autoimmune diabetes? The overload hypothesis. Diabetologia 49:20–24PubMedCrossRef Dahlquist G (2006) Can we slow the rising incidence of childhood-onset autoimmune diabetes? The overload hypothesis. Diabetologia 49:20–24PubMedCrossRef
6.
go back to reference Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC (2004) Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 47:1661–1667PubMedCrossRef Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC (2004) Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 47:1661–1667PubMedCrossRef
7.
go back to reference Bingley PJ, Mahon JL, Gale EAM, for the European Nicotinamide Diabetes Intervention Trial (ENDIT) Group (2008) Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 31:146–150PubMedCrossRef Bingley PJ, Mahon JL, Gale EAM, for the European Nicotinamide Diabetes Intervention Trial (ENDIT) Group (2008) Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 31:146–150PubMedCrossRef
8.
go back to reference Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP, for the Diabetes Prevention Trial-Type 1 Study Group (2007) Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care 30:2314–2320PubMedCrossRef Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP, for the Diabetes Prevention Trial-Type 1 Study Group (2007) Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care 30:2314–2320PubMedCrossRef
9.
go back to reference Larsson HE, Lynch K, Lernmark B et al (2005) Diabetes associated HLA genotypes affect birthweight in the general population. Diabetologia 48:1484–1491PubMedCrossRef Larsson HE, Lynch K, Lernmark B et al (2005) Diabetes associated HLA genotypes affect birthweight in the general population. Diabetologia 48:1484–1491PubMedCrossRef
10.
go back to reference Järvinen TM, Harjutsalo V, Kinnunen L, Miettinen ME, Tuomilehto-Wolf E, Tuomilehto J (2008) A population-specific diabetogenic haplotype HLA-A2, Cw1, B56, DR4, DQ8 is associated with high birthweight in Finnish diabetic families. Genes Immun 9:207–213PubMedCrossRef Järvinen TM, Harjutsalo V, Kinnunen L, Miettinen ME, Tuomilehto-Wolf E, Tuomilehto J (2008) A population-specific diabetogenic haplotype HLA-A2, Cw1, B56, DR4, DQ8 is associated with high birthweight in Finnish diabetic families. Genes Immun 9:207–213PubMedCrossRef
11.
go back to reference Hummel M, Marienfeld S, Huppmann M et al (2007) Fetal growth is increased by maternal type 1 diabetes and HLA DR4-related gene interactions. Diabetologia 50:850–858PubMedCrossRef Hummel M, Marienfeld S, Huppmann M et al (2007) Fetal growth is increased by maternal type 1 diabetes and HLA DR4-related gene interactions. Diabetologia 50:850–858PubMedCrossRef
12.
go back to reference Knip M, Reunanen A, Virtanen SM, Nuutinen M, Viikari J, Akerblom HK (2008) Does the secular increase in body mass in children contribute to the increasing incidence of type 1 diabetes? Pediat Diabetes 9:46–49CrossRef Knip M, Reunanen A, Virtanen SM, Nuutinen M, Viikari J, Akerblom HK (2008) Does the secular increase in body mass in children contribute to the increasing incidence of type 1 diabetes? Pediat Diabetes 9:46–49CrossRef
13.
go back to reference Hyppönen E, Virtanen SM, Kenward MG, Knip M, Akerblom HK, the Childhood Diabetes in Finland Study Group (2000) Obesity, increased linear growth, and risk of type 1 diabetes in children. Diabetes Care 23:1755–1760PubMedCrossRef Hyppönen E, Virtanen SM, Kenward MG, Knip M, Akerblom HK, the Childhood Diabetes in Finland Study Group (2000) Obesity, increased linear growth, and risk of type 1 diabetes in children. Diabetes Care 23:1755–1760PubMedCrossRef
14.
go back to reference Ziegler AG, Hummel M, Schenker M, Bonifacio E (1999) Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48:460–468PubMedCrossRef Ziegler AG, Hummel M, Schenker M, Bonifacio E (1999) Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48:460–468PubMedCrossRef
15.
go back to reference Kromeyer-Hauschild K, Wabitsch M et al (2001) Perzentile für den body-mass-index für das kinder- und jugendalter unter heranziehung verschiedener stichproben. Monatsschr Kinderheilkd 8:807–818; article in GermanCrossRef Kromeyer-Hauschild K, Wabitsch M et al (2001) Perzentile für den body-mass-index für das kinder- und jugendalter unter heranziehung verschiedener stichproben. Monatsschr Kinderheilkd 8:807–818; article in GermanCrossRef
16.
go back to reference Arbeitsgemeinschaft adipositas im kindes- und jugendalter: body-mass-index für deutsche kinder und jugendliche. Available from www.mybmi.de, accessed 20 March 2008 Arbeitsgemeinschaft adipositas im kindes- und jugendalter: body-mass-index für deutsche kinder und jugendliche. Available from www.​mybmi.​de, accessed 20 March 2008
17.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef
18.
go back to reference Steinberger J, Daniels SR (2003) Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 107:1448–1453PubMedCrossRef Steinberger J, Daniels SR (2003) Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 107:1448–1453PubMedCrossRef
19.
go back to reference Dietz WH, Robinson TN (1998) Use of the body mass index (BMI) as a measure of overweight in children and adolescents. J Pediatr 132:191–193PubMedCrossRef Dietz WH, Robinson TN (1998) Use of the body mass index (BMI) as a measure of overweight in children and adolescents. J Pediatr 132:191–193PubMedCrossRef
20.
go back to reference Szadkowska A, Pietrzak I, Mianowska B et al (2008) Insulin sensitivity in type 1 diabetic children and adolescents. Diabetic Medicine 25:282–288PubMedCrossRef Szadkowska A, Pietrzak I, Mianowska B et al (2008) Insulin sensitivity in type 1 diabetic children and adolescents. Diabetic Medicine 25:282–288PubMedCrossRef
21.
go back to reference Moran A, Jacobs DR, Steinberger J et al (1999) Insulin resistance during puberty. Diabetes 48:2039–2044PubMedCrossRef Moran A, Jacobs DR, Steinberger J et al (1999) Insulin resistance during puberty. Diabetes 48:2039–2044PubMedCrossRef
22.
go back to reference Brandou F, Brun JF, Mercier J (2005) Limited accuracy of surrogates of insulin resistance during puberty in obese and lean children at risk for altered glucoregulation. J Clin Endocrinol Metab 90:761–767PubMedCrossRef Brandou F, Brun JF, Mercier J (2005) Limited accuracy of surrogates of insulin resistance during puberty in obese and lean children at risk for altered glucoregulation. J Clin Endocrinol Metab 90:761–767PubMedCrossRef
23.
go back to reference Bonifacio E, Pflüger M, Marienfeld S, Winkler C, Hummel M, Ziegler AG (2008) Maternal type 1 diabetes reduces the risk of islet autoantibodies: relationships with birthweight and maternal HbA1c. Diabetologia 51:1245–1252PubMedCrossRef Bonifacio E, Pflüger M, Marienfeld S, Winkler C, Hummel M, Ziegler AG (2008) Maternal type 1 diabetes reduces the risk of islet autoantibodies: relationships with birthweight and maternal HbA1c. Diabetologia 51:1245–1252PubMedCrossRef
24.
go back to reference Rolandsson O, Hägg E, Hampe C et al (1999) Glutamate decarboxylase (GAD65) and tyrosine phosphatase-like protein (IA-2) autoantibodies index in a regional population is related to glucose intolerance and body mass index. Diabetologia 42:555–559PubMedCrossRef Rolandsson O, Hägg E, Hampe C et al (1999) Glutamate decarboxylase (GAD65) and tyrosine phosphatase-like protein (IA-2) autoantibodies index in a regional population is related to glucose intolerance and body mass index. Diabetologia 42:555–559PubMedCrossRef
25.
go back to reference Lee CH, Reifsnyder PC, Naggert JK et al (2005) Novel leptin receptor mutation in NOD/LtJ mice suppresses type 1 diabetes progression: I. Pathophysiological analysis. Diabetes 54:2525–2532PubMedCrossRef Lee CH, Reifsnyder PC, Naggert JK et al (2005) Novel leptin receptor mutation in NOD/LtJ mice suppresses type 1 diabetes progression: I. Pathophysiological analysis. Diabetes 54:2525–2532PubMedCrossRef
26.
go back to reference Lee CH, Chen YG, Chen J et al (2006) Novel leptin receptor mutation in NOD/LtJ mice suppresses type 1 diabetes progression: II. Immunologic analysis. Diabetes 55:171–178PubMedCrossRef Lee CH, Chen YG, Chen J et al (2006) Novel leptin receptor mutation in NOD/LtJ mice suppresses type 1 diabetes progression: II. Immunologic analysis. Diabetes 55:171–178PubMedCrossRef
Metadata
Title
Is islet autoimmunity related to insulin sensitivity or body weight in children of parents with type 1 diabetes?
Authors
C. Winkler
S. Marienfeld
M. Zwilling
E. Bonifacio
A.-G. Ziegler
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1461-1

Other articles of this Issue 10/2009

Diabetologia 10/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine